Evidence map›Paper›PMID 37403319›Full record

ArticleClinical and molecular hepatology2023

Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis.

Ha Il Kim, Jihyun An, Seungbong Han, Ju Hyun Shim

Open access · goldAbstract readNetwork Meta-Analysis
In one paragraph

Article in Clinical and molecular hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Ha Il KimGastroenterology and Hepatology, Hanyang University College of Medicine, Guri, Korea.
Jihyun AnGastroenterology and Hepatology, Hanyang University College of Medicine, Guri, Korea.
Seungbong HanBiostatistics, College of Medicine, Korea University, Seoul, Korea.
Ju Hyun ShimAsan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Hanyang University Guri Hospital · KRKorea University · KRUlsan College · KR

Funding

Asan Institute for Life Sciences, Asan Medical Center 2022IP0046Korean Association for the Study of the LiverKorean Liver Foundation KASLKLF2018-05Ministry of Science and ICTNational Research Foundation of Korea 2022R1A2C3008956National Research Foundation of Korea RS-2022-00166674
6 · The paper itself

Abstract

BACKGROUND/

aimsThere is no clear consensus on the relative ranking of interventional and radiation techniques with indications similar to those of radiofrequency ablation (RFA) for the treatment of early hepatocellular carcinoma (HCC). We used a network meta-analysis to compare the efficacy of non-surgical treatments for early HCC.

methodsWe searched databases for randomized trials assessing the efficacy of loco-regional treatments for HCCs ≤5 cm with no extrahepatic spread or portal invasion. The primary outcome was the pooled hazard ratio (HR) for overall survival (OS), and secondary outcomes included overall and local progression-free survival (PFS). A frequentist network meta-analysis was performed, and the relative ranking of therapies was assessed with P-scores.

resultsNineteen studies comparing 11 different strategies in 2,793 patients were included. Chemoembolization plus RFA improved OS better than RFA alone (HR 0.52, 95% confidence interval [CI] 0.33-0.82; P-score=0.951). Cryoablation, microwave ablation, laser ablation, and proton beam therapy had similar effects on OS compared with RFA. For overall PFS, but not local PFS, only chemoembolization plus RFA performed significantly better than RFA (HR 0.61, 95% CI 0.42-0.88; P-score=0.964). Injection of percutaneous ethanol or acetic acid was significantly less effective than RFA for all measured outcomes, while no differences in progression outcomes were identified for other therapies included in the network.

conclusionOur results suggest that chemoembolization combined with RFA is the best option for local treatment of early HCC. Cases with potential contraindications for RFA may benefit from a tailored approach using thermal or radiation modalities.

Indexed as

Carcinoma, HepatocellularCatheter AblationChemoembolization, TherapeuticLiver NeoplasmsRadiofrequency AblationHumansRetrospective StudiesTreatment OutcomeHepatocellular carcinomaLoco-regional treatmentNetwork meta-analysisRadiofrequency ablationSurvival

Identifiers

PMID37403319
PMCPMC10577337
OpenAlexW4383186865

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.